• 1 Accessed on January 4, 2013.
  • 2
    Serruys PW, De Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 2002;287:3215-3222.
  • 3
    Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-1718.
  • 4
    Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins-mechanisms and consequences. Curr Drug Saf 2009;4:209-228.
  • 5
    Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005;41:690.
  • 6
    Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009;29:412-422.
  • 7
    Reuben A, Koch DG, Lee WM, and the Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-2076.
  • 8
    Björsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144:1419-1425.
  • 9
    Björnsson E, Jacbosen E, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012;56:374-380.
  • 10
    Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug Induced Liver Injury Network (DILIN) prospective study: rationale, design, and conduct. Drug Saf 2009;l32:55-68.
  • 11
    Chalasani N, Fontana RJ, Bonkvosky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States. Gastroenterology 2008;135:1924-1934.
  • 12
    Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011;141:1665-1672.
  • 13
    Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
  • 14
    Kleiner DE, Chalasani N, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014;59:661-670.
  • 15
    Alla V, Abraham J, Siddiqui J, Raina D, Wu G, Chalasani N, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 2006;40:757-761.
  • 16 Accessed on December 1, 2013.
  • 17
    Nakad A, Bataille L, Hamoir V, Sempoux C, Horsman Y. Atorvastatin-induced hepatitis with the absence of cross-toxicity with simvastatin. Lancet 1999;353:1763-1764.
  • 18
    Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005;118:618-624.
  • 19
    Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol 2003;39:1095-1097.
  • 20
    Sreenarasinhaiah J, Shiels P, Lisker-Melman M. Multiorgan failure induced by atorvastatin. Am J Med 2002;113:348-349.
  • 21
    Ridruejo E, Mando OG. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. J Hepatol 2002;37:165-166.
  • 22
    Chen YW, Lai HW, Wang TD. Marked elevation of liver transaminases after high-dose fluvastatin unmasks chronic hepatitis C: safety and rechallenge. Acta Neurol Taiwan 2007;16:163-167.